Table 2.
Best disease responses and survival rate data (n=21).
| Variable | Primary liver tumor | PVTT | |||||||
|---|---|---|---|---|---|---|---|---|---|
| RECIST 1.1 | mRECIST | ||||||||
| All (n=21) | Vp3 (n=11) | Vp4 (n=10) | All (n=21) | Vp3 (n=11) | Vp4 (n=10) | ||||
| CR-no.(%) | 0 | 0 | 0 | 3 (14.3) | 2 (9.5) | 1 (4.8) | 7 (33.3) | ||
| PR-no.(%) | 8 (38.1) | 4 (19.0) | 4 (19.0) | 7 (33.3) | 4 (19.0) | 3 (14.3) | 9 (42.9) | ||
| SD-no.(%) | 13 (61.9) | 7 (33.3) | 6 (28.6) | 11 (52.4) | 5 (23.8) | 6 (28.6) | 5 (23.8) | ||
| PD-no.(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| ORR-no.(%) | 8 (38.1) | 4 (19.0) | 4 (19.0) | 10 (47.6) | 6 (28.6) | 4 (19.0) | 16 (76.2) | ||
| DCR-no.(%) | 21 (100) | 11 (52.4) | 10 (47.6) | 21 (100) | 11 (52.4) | 10 (47.6) | 21 (100) | ||
| Progression-free survival rate (n=21) | |||||||||
| 6-month, % (95% CI) | 57.1% (95%CI 46.3%-67.9%) | ||||||||
| Overall survival rate (n=21) | |||||||||
| 6-month, % (95% CI) | 81.0% (95%CI 72.4%-89.6%) | ||||||||
| 12-month, % (95% CI) | 52.4% (95%CI 41.5%-63.3%) | ||||||||
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PVTT, portal vein tumor thrombus.